Thank you very much, Madam Chair, for the opportunity to appear in front of this committee again.
We appreciate the opportunity to return to discuss the issue of post-market surveillance. I know this committee has heard from many excellent witnesses, and we're pleased to appear again to provide additional highlights of our work in this area and to respond to any questions you have.
I'd like to turn it over to Dr. Marc Berthiaume to take us through the opening comments. Dr. Berthiaume is director of the marketed pharmaceuticals and medical devices bureau in the marketed health products directorate at Health Canada. As such, he works on the front lines of post-market surveillance of pharmaceuticals and medical devices. In addition to his duties at Health Canada, Dr. Berthiaume is a physician who continues to practise medicine on a part-time basis.